

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

GENENTECH, INC.
Patent Owner

U.S. Patent No. 6,407,213

Case IPR2016-
Unassigned

**EXPERT DECLARATION OF DR. EDUARDO A. PADLAN
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF
PATENT NO. 6,407,213**

TABLE OF CONTENTS

	<u>Page</u>
I. QUALIFICATIONS AND BACKGROUND	1
A. Education and Experience	1
B. Bases for Opinions and Materials Considered	5
C. Previous Litigation Experience	5
D. Scope of Work	5
II. Legal Standards	6
III. Person of Ordinary Skill in the Art	11
IV. Summary of Opinions	12
V. The '213 Patent [Ex. 1001]	19
VI. Background	37
A. Antibody Structure and Function	37
B. Monoclonal Antibodies Expanded Therapeutic and Diagnostic Uses of Antibodies	39
C. Immunogenic Reaction in Humans With Monoclonal Antibody Therapy	41
D. Molecular Characterization of Antibody Structure and Function	42
E. Antigen Binding Regions	45
F. Framework Region Important for Antigen Binding	51
G. Chimeric Antibodies	55
H. Antibody Humanization	57
VII. Scope and Content of the Prior Art References	70
A. EP 0403156 “Improved Monoclonal Antibodies Against the Human Alpha/Beta T-Cell Receptor, Their Production and Use” Published December 19, 1990 (“Kurrle”) [Ex. 1071]	70
B. Queen et al. “A Humanized Antibody that Binds to the Interleukin 2 Receptor” <i>PNAS</i> 86:10029-33 (1989) (“Queen 1989”) [Ex. 1034]	73
C. PCT Publication No. WO 90/07861 (“Queen 1990”) [Ex. 1050]	76
D. Furey et al. “Structure of a Novel Bence-Jones Protein (Rhe) Fragment at 1.6 Å Resolution,” <i>J. Mol. Biol.</i> 167:661-692 (1983) [Ex. 1125]	80
E. Protein Data Bank Database	81

TABLE OF CONTENTS
(continued)

	<u>Page</u>
F. Tramontano et al. “Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins” J. Mol. Biol. 215:175-182 (1990) (“Tramontano”) [Ex. 1051]	83
G. Kabat et al. “Sequences of Proteins of Immunological Interest” 4 th Ed., pp. iii, 41-49, 167-176 (1987) (“Kabat 1987”) [Ex. 1052]	84
H. Hudziak et al. “p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor” Mol Cell Biol 9:1165-1172 (1989) (“Hudziak”) [Ex. 1021]	85
I. Chothia, C. et al. “Domain Association in Immunoglobulin Molecules: The Packing of Variable Domains” J. Mol. Biol. 186:651-663 (1985) (“Chothia 1985”) [Ex. 1063]	86
J. Chothia and Lesk. “Canonical Structures for the Hypervariable Regions of Immunoglobulins” J. Mol. Biol. 196:901-917 (1987) (“Chothia & Lesk”) [Ex. 1062]	87
K. Chothia, C. et al. “Conformations of Immunoglobulin Hypervariable Regions” Nature 342:877-883 (1989) (“Chothia 1989”) [Ex. 1049]	87
VIII. <u>UNPATENTABILITY OF THE '213 PATENT</u>	88
A. Claims 1, 2, 25, 29, 63, 66, 71, 75, 76, 78, 80 and 81 of the '213 Patent are Anticipated by Kurrle [Ex. 1071]	88
1. Claim 1 of the '213 patent is anticipated by Kurrle	88
2. Dependent claims 2, 25 and 29 are anticipated by Kurrle	90
3. Independent claim 63 is anticipated by Kurrle	92
4. Independent claim 66 and dependent claims 71, 72, 75 and 76 are anticipated by Kurrle	94
5. Independent claim 80 and dependent claim 81 are anticipated by Kurrle	95
B. Claims 1, 2, 4, 29, 62, 63, 64, 80 and 81 of the '213 Patent are Anticipated by Queen 1990	97
1. Independent Claim 1 of the '213 Patent is anticipated by Queen 1990 [Ex. 1050]	97

TABLE OF CONTENTS
(continued)

	<u>Page</u>
2. Dependent Claim 2 of the '213 Patent is anticipated by Queen 1990.....	103
3. Dependent Claim 4 of the '213 Patent is anticipated by Queen 1990.....	104
4. Dependent Claim 29 of the '213 Patent is anticipated by Queen 1990	105
5. Independent Claim 62 of the '213 Patent is anticipated by Queen 1990	105
6. Independent Claim 63 of the '213 Patent is anticipated by Queen 1990	106
7. Dependent Claim 65 of the '213 Patent is anticipated by Queen 1990	108
8. Independent Claim 64 of the '213 Patent is anticipated by Queen 1990	110
9. Independent Claim 80 of the '213 Patent is anticipated by Queen 1990	112
10. Dependent Claim 81 of the '213 Patent is anticipated by Queen 1990	114
C. Claims 1, 2, 4, 12, 25, 29, 62-67, 69 and 71-81 of the '213 Patent are obvious over Queen 1990 in view of Kurrle, and Chothia 1985 or Chothia & Lesk.....	114
1. Claim 1 is obvious over Queen 1990 and Kurrle	117
2. Claims 2, 25 and 29 are obvious over Queen 1990 and Kurrle.....	120
3. Claim 4 is obvious over Queen 1990 and Kurrle	122
4. Claim 12 is obvious over Queen 1990 and Kurrle, in view of Furey	123
5. Claim 62 is obvious over Queen 1990 in view of Kurrle ...	125
6. Claim 63 is obvious over Queen 1990 in view of Kurrle ...	126
7. Claim 64 is obvious over Queen 1990 in view of Kurrle ...	127
8. Claim 65 is obvious over Queen 1990 in view of Kurrle ...	129
9. Claim 66 is obvious over Queen 1990 in view of Kurrle ...	132
10. Claims 67, 71, 72, 74, 75, 76 and 78 are obvious over Queen 1990 in view of Kurrle and Chothia 1985.....	133
11. Claim 69 is obvious over Queen 1990 in view of Kurrle ...	136
12. Claims 73, 77 and 79 are obvious in view of Queen 1990, Kurrle and Chothia & Lesk.....	136

TABLE OF CONTENTS
(continued)

	<u>Page</u>
13. Claims 80 and 81 are obvious over Queen 1990 in view of Kurrle.....	142
D. Claims 1, 2, 4, 12, 25, 29, 62-67, 69 and 71-81 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database	144
1. Independent Claim 1 of the '213 Patent is obvious in view of Queen 1989 and the PDB database	145
2. Independent Claim 1 of the '213 Patent is obvious in view of Queen 1990 and the PDB database	160
3. Dependent Claims 2, 12, 25 and 29 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database	163
4. Dependent claim 4 of the '213 Patent is obvious in view of Queen 1990 and the PDB database	164
5. Independent Claim 62 of the '213 Patent is obvious in view of Queen 1990 and the PDB database	164
6. Independent Claim 63 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	165
7. Independent Claim 64 of the '213 Patent is obvious in view of Queen 1990 and the PDB database	166
8. Independent Claim 66 of the '213 Patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	168
9. Dependent Claims 67, 71-74 and 78 of the '213 Patent are obvious in view of Queen 1989 or Queen 1990 and the PDB database	170
10. Dependent Claim 72 of the '213 patent is obvious in view of Queen 1989 or Queen 1990, and the PDB database.....	171
11. Dependent Claim 75 of the '213 patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database.....	173
12. Dependent Claim 75 of the '213 patent is obvious in view of Queen 1989 or Queen 1990 and the PDB database, and further in view of Tramontano	174

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.